Sydney Jennings

Three-year BE HEARD data show bimekizumab sustains HS lesion clearance, cuts draining tunnels, and improves severity and quality of life.

FDA insulin updates, new obesity drug data, vaccine hesitancy strategies, and depression screening insights are featured in this week’s episode.

FDA clears a dissolvable sildenafil oral film for erectile dysfunction, offering discreet, water-free dosing and strong phase 3 results ahead of 2026 launch.

Researchers found that 58% of infants with atopic dermatitis achieved a 75% improvement in EASI-75 at week 4 with once-daily roflumilast cream 0.05%.

A new study reveals icotrokinra's comparable efficacy to existing therapies, offering hope for treatment-refractory patients facing resistance challenges.

The FDA delays approval of Anaphylm, a sublingual epinephrine film for anaphylaxis, citing administration and human factors study deficiencies.

GRAIL advances cancer detection with FDA application for Galleri, a groundbreaking blood test aimed at early detection of multiple cancers.

Roche's CT-388 shows promising results with 22.5% weight loss in a phase 2 trial, advancing obesity treatment options significantly.

Centanafadine's FDA priority review signals potential innovation in ADHD treatment, offering a new nonstimulant option for diverse patient needs.

Colorectal cancer emerges as the top cancer killer for US adults under 50, highlighting urgent needs for early detection and screening strategies.

The FDA updates Afrezza's prescribing information, enhancing dosing guidance for adults switching from injected insulin to improve glycemic control.

ACON Laboratories launches the first FDA-cleared at-home test for RSV, influenza, and COVID-19, enhancing respiratory symptom management for families.

National health trends for 2025 show a complex mix of improved cancer screenings alongside rising chronic conditions and affordability gaps.

Results show significant concerns about topical steroid use in chronic skin diseases, highlighting the need for proactive long-term management strategies.

Sebela Pharmaceuticals seeks FDA approval for tegoprazan, a new treatment for GERD, targeting heartburn, erosive esophagitis, and maintenance healing.

A study reveals that using population-based eGFR percentiles can enhance early detection of chronic kidney disease and improve patient outcomes.

Your daily dose of the clinical news you may have missed.

This episode reviews intranasal epinephrine use, pediatric atopic dermatitis data, dementia screening tools, adolescent TMS, and oral PCSK9 therapy.

New phase 3 data reveals lumateperone significantly boosts remission rates in adults with major depressive disorder, offering hope for lasting relief.

Your daily dose of the clinical news you may have missed.

Results from the SPACE clinical trial showed fremanezumab reduced monthly migraine days versus placebo in children and adolescents with episodic migraine.

Your daily dose of the clinical news you may have missed.

Global trends reveal a growing burden of hypertension-related CKD despite advances in blood pressure management.

A recent study reveals declining chronic kidney disease rates in children but rising incidence among young adults, highlighting urgent public health concerns.

Your daily dose of the clinical news you may have missed.

FDA requests removal of suicidal ideation warnings from GLP-1 receptor agonist labeling after a comprehensive review found no increased risk.

Your daily dose of the clinical news you may have missed.

Weight-loss interventions significantly enhance psoriasis severity and quality of life, emphasizing their role in effective psoriasis management strategies.

Your daily dose of the clinical news you may have missed.

FDA identifies deficiencies in Anaphylm's NDA, impacting labeling discussions, while review continues for this innovative treatment for severe allergic reactions.